Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|March 17, 2022
Daily Medication Pearl: Mepolizumab (Nucala)
Author(s)Saro Arakelians, PharmD
Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.
Advertisement
Medication Pearl of the Day: Mepolizumab (Nucala)
Indication: Nucala is an interleukin-5 (IL-5) antagonist monoclonal antibody (immunoglobulin G1 kappa) indicated for the add-on maintenance treatment of adult and pediatric patients 6 years of age and older with severe asthma and with an eosinophilic phenotype.
Insight:
- Dosing: 100 mg administered subcutaneously once every 4 weeks for severe asthma in patients 12 years of age and older.
- Dosage forms: For injection 100 mg of lyophilized powder in a single-dose vial for reconstitution.
- Adverse events: Most common adverse reactions (incidence ≥5%) include headache, injection site reaction, back pain, and fatigue.
- Mechanism of action: Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been definitively established.
- Manufacturer: GlaxoSmithKline
Sources:
Advertisement
Related to this article
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5